PCAB (vonoprazan)

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a biopharmaceutical company committed to developing and commercializing innovative treatments for gastrointestinal diseases, specifically those related to acid. The company holds exclusive rights in the U.S., Europe, and Canada to a novel potassium-competitive acid blocker (PCAB) and is advancing late-stage clinical programs for NERD and EoE. With a seasoned leadership team and a focus on a dormant therapeutic area, Phathom aims to disrupt the status quo and significantly improve patient lives. Its strategic direction involves progressing its pipeline through clinical trials to bring new therapeutic options to market.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a biopharmaceutical company committed to developing and commercializing innovative treatments for gastrointestinal diseases, specifically those related to acid. The company holds exclusive rights in the U.S., Europe, and Canada to a novel potassium-competitive acid blocker (PCAB) and is advancing late-stage clinical programs for NERD and EoE. With a seasoned leadership team and a focus on a dormant therapeutic area, Phathom aims to disrupt the status quo and significantly improve patient lives. Its strategic direction involves progressing its pipeline through clinical trials to bring new therapeutic options to market.

Therapeutic Areas